Safety and immunogenicity of heterologous prime/boost inactivated COVID-19 vaccine and viral vector vaccine: an experimental clinical study

Phase 3

Completed

• Conditions: Immunogenicity; COVID-19, SARS-CoV-2, Priming effect, Boost, Vaccine, Clinical trial, Antibody, Immunity, Interchangeability

• Registration Number: TCTR20210628005
• Lead Sponsor: ational Research Council of Thailand (NRCT)

Brief Summary

Given the shorter completion time of two doses, heterologous CoronaVac followed by ChAdOx1-S can be considered as an alternative regimen to homologous efficacy-proven ChAdOx1-S in countries with circulating variants. Additional studies on the efficacy and durability of immune responses induced by heterologous vaccine regimens are warranted.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-06-28
• Study Completion: 2021-09-30
• Results First Posted: 2021-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Healthy individuals above 18 years of age
2. Have never been infected with SARS-CoV-2
3. Have never been vaccinated with COVID-19 vaccine
4. Not in the immunocompromised status

Exclusion Criteria

1. Are being infected with COVID-19
2. Bleeding disorders

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
immunogenicity 1 month post two doses anti-spike RBD IgG

Secondary Outcome Measures

Name	Time	Method
safety 7 days after vaccination incidence of adverse events